Singapore, Nov. 6 -- Abbott, the global healthcare leader, and Novo, a global leader in treatments for serious chronic diseases, have announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type 2 diabetes across Asia Pacific.

Under the agreement, Abbott will commercialise Plosbrio(R) (semaglutide), developed and manufactured by Novo, across Singapore and other Asia Pacific countries, expanding access to an evidence-based diabetes treatment in a region facing a rapidly growing diabetes burden.

Plosbrio(R) is a second brand of Ozempic(R), one of the world's most prescribed GLP-1 RA (receptor agonist) molecules.

The agreement represents a new regional approach to broadening access...